DK3558369T3 - Antistoffer, der specifikt binder til humant il-15, og anvendelse heraf - Google Patents

Antistoffer, der specifikt binder til humant il-15, og anvendelse heraf Download PDF

Info

Publication number
DK3558369T3
DK3558369T3 DK17883800.9T DK17883800T DK3558369T3 DK 3558369 T3 DK3558369 T3 DK 3558369T3 DK 17883800 T DK17883800 T DK 17883800T DK 3558369 T3 DK3558369 T3 DK 3558369T3
Authority
DK
Denmark
Prior art keywords
antibodies
human
specifically binding
binding
specifically
Prior art date
Application number
DK17883800.9T
Other languages
Danish (da)
English (en)
Inventor
Matthew Pollard
Anthony Gerard Doyle
Lynn Dorothy Poulton
Adam William Clarke
David Jose Simon Laine
Original Assignee
Cephalon Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Llc filed Critical Cephalon Llc
Application granted granted Critical
Publication of DK3558369T3 publication Critical patent/DK3558369T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5443—IL-15

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
DK17883800.9T 2016-12-21 2017-12-21 Antistoffer, der specifikt binder til humant il-15, og anvendelse heraf DK3558369T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662437143P 2016-12-21 2016-12-21
PCT/US2017/067917 WO2018119246A1 (en) 2016-12-21 2017-12-21 Antibodies that specifically bind to human il-15 and uses thereof

Publications (1)

Publication Number Publication Date
DK3558369T3 true DK3558369T3 (da) 2025-05-19

Family

ID=62627610

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17883800.9T DK3558369T3 (da) 2016-12-21 2017-12-21 Antistoffer, der specifikt binder til humant il-15, og anvendelse heraf

Country Status (30)

Country Link
US (2) US11267883B2 (cg-RX-API-DMAC7.html)
EP (2) EP4585261A3 (cg-RX-API-DMAC7.html)
JP (2) JP7155126B2 (cg-RX-API-DMAC7.html)
KR (2) KR102706743B1 (cg-RX-API-DMAC7.html)
CN (1) CN110234349B (cg-RX-API-DMAC7.html)
AR (1) AR110414A1 (cg-RX-API-DMAC7.html)
AU (2) AU2017382850B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019012570A8 (cg-RX-API-DMAC7.html)
CA (1) CA3046387A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019001729A1 (cg-RX-API-DMAC7.html)
DK (1) DK3558369T3 (cg-RX-API-DMAC7.html)
EA (1) EA201991514A1 (cg-RX-API-DMAC7.html)
ES (1) ES3026508T3 (cg-RX-API-DMAC7.html)
FI (1) FI3558369T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250482T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071878T2 (cg-RX-API-DMAC7.html)
IL (1) IL267113B2 (cg-RX-API-DMAC7.html)
LT (1) LT3558369T (cg-RX-API-DMAC7.html)
MA (1) MA47130B1 (cg-RX-API-DMAC7.html)
MD (1) MD3558369T2 (cg-RX-API-DMAC7.html)
MX (2) MX2019007357A (cg-RX-API-DMAC7.html)
PE (1) PE20191497A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019501453A1 (cg-RX-API-DMAC7.html)
PL (1) PL3558369T3 (cg-RX-API-DMAC7.html)
PT (1) PT3558369T (cg-RX-API-DMAC7.html)
RS (1) RS66900B1 (cg-RX-API-DMAC7.html)
SI (1) SI3558369T1 (cg-RX-API-DMAC7.html)
UA (1) UA126284C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018119246A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201903848B (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102207770B1 (ko) 2013-08-05 2021-01-26 트위스트 바이오사이언스 코포레이션 드 노보 합성된 유전자 라이브러리
CA2975852A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
EP3350314A4 (en) 2015-09-18 2019-02-06 Twist Bioscience Corporation OLIGONUCLEIC ACID VARIANT LIBRARIES VARIANT AND SYNTHESIS THEREOF
CN108698012A (zh) 2015-09-22 2018-10-23 特韦斯特生物科学公司 用于核酸合成的柔性基底
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
EP4585261A3 (en) 2016-12-21 2025-08-13 Cephalon LLC Antibodies that specifically bind to human il-15 and uses thereof
EP3586255B1 (en) 2017-02-22 2025-01-15 Twist Bioscience Corporation Nucleic acid based data storage
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
IL271205B2 (en) 2017-06-12 2025-02-01 Twist Bioscience Corp Methods for assembling continuous nucleic acids
CN111566125A (zh) 2017-09-11 2020-08-21 特韦斯特生物科学公司 Gpcr结合蛋白及其合成
WO2019079769A1 (en) 2017-10-20 2019-04-25 Twist Bioscience Corporation HEATED NANOWELLS FOR THE SYNTHESIS OF POLYNUCLEOTIDES
IL275818B2 (en) 2018-01-04 2024-10-01 Twist Bioscience Corp Dna-based digital information storage
IL278771B2 (en) 2018-05-18 2025-09-01 Twist Bioscience Corp Polynucleotides, reagents and methods for nucleic acid hybridization
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
US11828385B2 (en) 2018-12-25 2023-11-28 Ntn Corporation Flow control valve seal and flow control valve device
EP3902816A4 (en) 2018-12-26 2022-09-14 Twist Bioscience Corporation HIGHLY ACCURATE POLYNUCLEOTIDE DE NOVO SYNTHESIS
WO2020176678A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for glp1 receptor
WO2020176680A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
AU2020298294A1 (en) 2019-06-21 2022-02-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
CN115023440B (zh) 2019-09-23 2025-09-12 特韦斯特生物科学公司 结合CD3ε的抗体
WO2021061829A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for crth2
JP2023504572A (ja) * 2019-12-09 2023-02-03 ツイスト バイオサイエンス コーポレーション アデノシン受容体のためのバリアント核酸ライブラリー
WO2022082201A1 (en) * 2020-10-16 2022-04-21 Genentech, Inc. Anti-cleaved icaspase substrate antibodies and methods of use
US12202905B2 (en) 2021-01-21 2025-01-21 Twist Bioscience Corporation Methods and compositions relating to adenosine receptors
CN113185600A (zh) * 2021-05-28 2021-07-30 苏州复融生物技术有限公司 一种新型白介素15突变体多肽的开发及其应用
AU2023317825A1 (en) 2022-08-04 2025-02-13 Novartis Pharma Ag Il-15 inhibitors useful for the treatment of atopic dermatitis
CN118894934A (zh) * 2023-05-05 2024-11-05 北京智仁美博生物科技有限公司 抗人il-15的抗体及其用途
CN117209605B (zh) * 2023-11-09 2024-01-30 北京百普赛斯生物科技股份有限公司 特异性结合il-15的抗体及其应用
WO2025227052A1 (en) * 2024-04-26 2025-10-30 Cephalon Llc Doses and formulations of anti-il-15 antibody for the treatment of immune diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7132510B2 (en) * 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
US7329405B2 (en) * 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
EP1425389B1 (en) * 2001-08-23 2011-11-02 Genmab A/S Human antibodies specific for interleukin 15 (il-15)
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1578799B8 (en) * 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
CN1780856A (zh) * 2003-02-26 2006-05-31 根马布股份公司 白介素15(il－15)的特异性人抗体
AR050693A1 (es) * 2004-08-11 2006-11-15 Zheng Xin Xiao Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune.
US8048992B2 (en) 2005-02-28 2011-11-01 Institute For Antibodies Co., Ltd. Anti-IgSF4 antibody and utilization of the same
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
SI2602323T1 (en) 2007-06-01 2018-05-31 Open Monoclonal Technology, Inc. Compositions and procedures for inhibiting endogenous immunoglobin gene and the formation of transgenic human idiopathic antibodies
AR068767A1 (es) * 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
EP2517556B2 (en) * 2009-07-08 2023-03-22 Kymab Limited Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains
IN2012DN02634A (cg-RX-API-DMAC7.html) * 2009-10-15 2015-09-04 Abbvie Inc
EP2550529B1 (en) 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
JP5972871B2 (ja) * 2010-07-20 2016-08-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｉｌ−２３ヘテロ二量体特異的抗体
JP5820688B2 (ja) 2011-03-23 2015-11-24 株式会社Kri 多糖類の溶解に用いられる溶媒ならびに該溶媒を用いた成形体および多糖類誘導体の製造方法
MX2014002053A (es) * 2011-08-23 2014-04-25 Roche Glycart Ag Anticuerpos anti -mcsp y metodos de uso.
CN109022465B (zh) * 2011-10-28 2022-04-29 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP2963057A1 (en) * 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15
JP6862351B2 (ja) * 2015-03-31 2021-04-21 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 新規ｉｌ３３型、変異型のｉｌ３３、抗体、アッセイ及びそれらの使用方法
WO2017217985A1 (en) 2016-06-15 2017-12-21 Amgen Inc. Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease
PE20240950A1 (es) 2016-10-14 2024-05-06 Xencor Inc PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
EP4585261A3 (en) 2016-12-21 2025-08-13 Cephalon LLC Antibodies that specifically bind to human il-15 and uses thereof

Also Published As

Publication number Publication date
PL3558369T3 (pl) 2025-06-23
WO2018119246A1 (en) 2018-06-28
UA126284C2 (uk) 2022-09-14
KR20190097094A (ko) 2019-08-20
CN110234349A (zh) 2019-09-13
KR102706743B1 (ko) 2024-09-19
BR112019012570A8 (pt) 2023-01-24
SI3558369T1 (sl) 2025-06-30
LT3558369T (lt) 2025-07-25
HRP20250482T1 (hr) 2025-06-20
US12410247B2 (en) 2025-09-09
IL267113B1 (en) 2024-05-01
IL267113B2 (en) 2024-09-01
MX2023014081A (es) 2023-12-06
US20220127352A1 (en) 2022-04-28
MX2019007357A (es) 2019-09-05
EP3558369B1 (en) 2025-03-26
RS66900B1 (sr) 2025-07-31
JP2020501583A (ja) 2020-01-23
ES3026508T3 (en) 2025-06-11
HUE071878T2 (hu) 2025-09-28
MD3558369T2 (ro) 2025-08-31
EP4585261A3 (en) 2025-08-13
BR112019012570A2 (pt) 2019-11-26
IL267113A (en) 2019-08-29
PT3558369T (pt) 2025-05-06
AU2017382850A1 (en) 2019-07-04
CL2019001729A1 (es) 2019-09-13
US11267883B2 (en) 2022-03-08
EP4585261A2 (en) 2025-07-16
PH12019501453A1 (en) 2020-06-15
CA3046387A1 (en) 2018-06-28
KR20230135691A (ko) 2023-09-25
MA47130A (fr) 2019-10-30
US20200270339A1 (en) 2020-08-27
AR110414A1 (es) 2019-03-27
EP3558369A4 (en) 2020-09-09
MA47130B1 (fr) 2025-05-30
AU2017382850B2 (en) 2024-11-21
FI3558369T3 (fi) 2025-05-02
AU2025201185A1 (en) 2025-03-13
EP3558369A1 (en) 2019-10-30
EA201991514A1 (ru) 2019-12-30
JP7155126B2 (ja) 2022-10-18
JP2022176324A (ja) 2022-11-25
ZA201903848B (en) 2023-02-22
PE20191497A1 (es) 2019-10-21
CN110234349B (zh) 2024-03-22

Similar Documents

Publication Publication Date Title
DK3558369T3 (da) Antistoffer, der specifikt binder til humant il-15, og anvendelse heraf
DK3592384T3 (da) Antistoffer, der specifikt binder til human il-1r7
IL282704A (en) De novo binding domain containing polypeptides and uses thereof
IL272524A (en) Clec9a binding agents and use thereof
HRP20181802T1 (hr) Protutijela koja vežu humani cd3
DK3097122T3 (da) Antistoffer, der binder beta-klotho-domæne 2, og fremgangsmåder til anvendelse deraf
DK3223845T3 (da) Heterodimere antistoffer, der binder cd3 og cd20
DK3110849T3 (da) Antistof, der binder erbb-2 og erbb-3
DK3122781T3 (da) Bispecifikke antistoffer, der binder til cd38 og cd3
DK3328889T3 (da) Bispecifikke antistofkonstruktioner, der binder dll3 og cd3
DK3370768T3 (da) Antistoffer som specifikt binder pd-1 og anvendelser deraf
DK3625263T3 (da) Anti-galectin- 9-antistoffer og anvendelser deraf
ZA201906813B (en) Antibody binding specifically to muc1 and use thereof
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
DK3303379T3 (da) Tigit-bindende midler og anvendelser deraf
DK3665198T3 (da) Antistoffer, der binder egfr og cmet
DK3328892T3 (da) Bispecifikke antistofkonstruktioner, der binder egfrviii og cd3
DK3922645T3 (da) Anti-pro/latent-myostatin-antistoffer og anvendelse heraf
DK3182999T3 (da) Anti-lag3-antistoffer og antigenbindingsfragmenter
DK3169733T3 (da) Forbedrede bindemiddelsammensætninger og anvendelser deraf
DK3710484T5 (da) Ctla-4-bindende antistoffer og anvendelser deraf
EP3708589A4 (en) BISPECIFIC ANTIBODIES THAT BIND TO CD40 AND EpCAM
EP3606963C0 (en) ANTIBODIES BINDING TO STEAP-1
IL266516B (en) An antibody that specifically binds to cd66c and its use
DK3507306T3 (da) Bispecifikke immunmodulatoriske antistoffer, der binder co-stimulerende og checkpoint-receptorer